MeBioS Biosensor Group, Faculteit Bio-Ingenieurswetenschappen, KU Leuven, Belgium.
Sensors (Basel). 2013 Jan 21;13(1):1353-84. doi: 10.3390/s130101353.
Major advancements in molecular biology and clinical diagnostics cannot be brought about strictly through the use of genomics based methods. Improved methods for protein detection and proteomic screening are an absolute necessity to complement to wealth of information offered by novel, high-throughput sequencing technologies. Only then will it be possible to advance insights into clinical processes and to characterize the importance of specific protein biomarkers for disease detection or the realization of "personalized medicine". Currently however, large-scale proteomic information is still not as easily obtained as its genomic counterpart, mainly because traditional antibody-based technologies struggle to meet the stringent sensitivity and throughput requirements that are required whereas mass-spectrometry based methods might be burdened by significant costs involved. However, recent years have seen the development of new biodetection strategies linking nucleic acids with existing antibody technology or replacing antibodies with oligonucleotide recognition elements altogether. These advancements have unlocked many new strategies to lower detection limits and dramatically increase throughput of protein detection assays. In this review, an overview of these new strategies will be given.
分子生物学和临床诊断学的重大进展不能仅仅通过使用基于基因组学的方法来实现。改进的蛋白质检测和蛋白质组筛选方法是绝对必要的，可以补充新型高通量测序技术提供的大量信息。只有这样，才能深入了解临床过程，并确定特定蛋白质生物标志物在疾病检测或实现“个性化医学”中的重要性。然而，目前大规模蛋白质组学信息仍然不像基因组学信息那样容易获得，主要是因为传统的基于抗体的技术难以满足严格的灵敏度和通量要求，而基于质谱的方法可能会受到高昂成本的影响。然而，近年来，人们已经开发出了将核酸与现有的抗体技术联系起来的新的生物检测策略，或者完全用寡核苷酸识别元件代替抗体。这些进展为降低检测限和大大提高蛋白质检测分析的通量解锁了许多新策略。在这篇综述中，将对这些新策略进行概述。
